Please assess the completion status of the following clinical trial:

Trial Title: Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject between 18 and 55 years of age.~* Healthy individuals without any significant medical conditions as determined by a screening performed at University.~* Adherence to the study dietary and medication restrictions.~* Willingness to refrain from smoking or use of tobacco or marijuana one week before the start of the study and until completion of the study which will be a total of 17 days.~* Ability to commit the time requested for this study.~Exclusion Criteria:~* Underweight (weighs less than 50kg or 110lb) or over weight \[body mass index (BMI) greater than 32\].~* Drug or alcohol abuse (more than 3 alcoholic drinks per day on a regular basis).~* History of intolerance or allergic reaction (e.g. rash) to efavirenz and/or voriconazole.~* Significant health conditions such heart, gastrointestinal disorders, liver, or kidney diseases that may be exacerbated during the course of the study.~* History or current psychiatric illness (e.g. depression, anxiety, or nervousness).~* History or current eye sight disturbances (e.g. blurred vision).~* Serious infection within the last 2 weeks.~* Blood donation within the past two months.~* Screening results that do not fall in a healthy range.~* Regularly taking prescriptions (except hormonal agents, e.g. oral contraceptives), over-the-counter, herbal or dietary supplements, and alternative medications and are unable or unwilling to stop taking them one week before and during the study periods.~* Female with a positive pregnancy test.~* Female breastfeeding.~* Females of child-bearing potential who are unable or unwilling to either practice abstinence or use appropriate birth control up until the study completion, which will take a total of 17 days.~* Participation in a research study involving intensive blood sampling and/or have use study drugs in the last two months.~* Employed or student under supervision of any of the investigators of this study.~* Inability to state a good understanding of this study including risks and requirements, and inability to follow the rules of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CYP2B6 (Type: EXPERIMENTAL): Healthy volunteers will receive Efavirenz and Vericonazole as follow:~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).